Physical activity can assist in weight loss in those who are experiencing obesity due to diabetes, which may decrease the risk of incontinence symptoms by reducing the amount of pressure placed on the pelvic floor
Ahmet Murat What we can support you with Clarifying if your thinning is linked to semaglutide hair loss , post-weight-loss stress, or an unrelated cause Reviewing your protein intake, ferritin, zinc, vitamin D, and other factors tied to nutrient deficiency hair loss Checking for signs of unmasking androgenetic alopecia Designing a recovery plan that suits your metabolism, not a generic template Recommending PRP, microneedling, or medical therapy when appropriate Guiding you through expectations what tends to come back, and what needs more direct support Evaluating transplant suitability only when the hair cycle is stable and the underlying cause is resolved You dont need to guess your way through this
[96] [98] [99] Several applications and approvals for generic semaglutide followed, both for type 2 diabetes [92] and weight loss
Key disclosures from company terms include: MEDVi states it does not directly provide medical or pharmacy services Payment does not guarantee the writing or dispensing of a prescription The site identifies itself as "an advertisement for services and not any specific medication" OpenLoop Health clinicians retain the decision to prescribe compounded GLP-1s to patients Entity Structure According to MEDVi's terms of use: "MEDVi does not provide any Healthcare Services through the Platform and is not licensed to practice medicine." MEDVi, LLC: Technology platform providing intake coordination, customer service, and payment processing OpenLoop Health: According to company disclosures, provides the network of licensed medical providers who conduct evaluations and make prescribing decisions Partner compounding pharmacies: According to the website, MEDVi partners with "multiple USA certified pharmacies" Pricing (As of December 26, 2025) Cost considerations are separate from medical appropriateness and should not influence prescribing decisions
This is a secondary-prevention result, not a general heart-health claim, and it belongs to the full obesity dose
